Every Form 4 that Fulgent Genetics, Inc. (FLGT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow FLGT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FLGT filings page.
Fulgent Genetics, Inc. (FLGT) reported that its CFO and Treasurer, Paul Kim, had 2,087 shares of common stock withheld on September 1, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 25, 2025. After this tax-withholding disposition, Kim directly holds 356,543 shares of Fulgent Genetics common stock.
Fulgent Genetics, Inc. (FLGT) reported that Chief Executive Officer and director Ming Hsieh had 4,392 shares of common stock withheld on September 1, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 25, 2025. After this tax-withholding disposition, he directly holds 885,952 shares of common stock. He also reports indirect ownership through the Ming Hsieh Trust, the Dynasty Trust (for which he disclaims any beneficial interest except for any pecuniary interest), a Uniform Transfers to Minors Act account, and an immediate family member’s account, where he or related parties have varying voting and dispositive powers. No Rule 10b5-1 trading plan is reported for these transactions.
Fulgent Genetics, Inc. (FLGT) reported that Chief Scientific Officer Hanlin Gao sold 1,673 shares of common stock on September 2, 2026 at a weighted-average price of $19.66 per share. According to the disclosure, the sale was made to satisfy tax withholding obligations arising from the vesting of restricted stock units. Following this sale, Gao directly holds 986,117 shares of Fulgent Genetics common stock.
Fulgent Genetics, Inc. (FLGT) reports that President and COO Jian Xie sold 2,127 shares of common stock on September 2, 2026 at a weighted-average price of $19.6564 per share to satisfy tax withholding obligations arising from vesting of previously granted restricted stock units. Following this sale, he directly holds 359,924 shares and has indirect ownership of 220,816 shares held by The Hsieh Family Dynasty Trust, where he serves on the investment committee and disclaims beneficial interest except for any pecuniary interest. No Rule 10b5-1 trading plan is reported for these transactions.
Fulgent Genetics, Inc. (FLGT) reported an insider tax-withholding transaction by Chief Executive Officer and director Ming Hsieh. On 2026-08-26, 2,949 shares of common stock were withheld at $19.81 per share to satisfy tax obligations arising from the vesting of restricted stock units granted on February 26, 2024.
After this withholding, Hsieh directly held 890,344 common shares. He also has indirect holdings through The Ming Hsieh Trust, the Dynasty Trust (where he disclaims beneficial interest except for any pecuniary interest), a Uniform Transfers to Minor Act account for which he is custodian holding 1,000 shares, and 1,000 shares held by an immediate family member in the same household.
For Fulgent Genetics, Inc. (FLGT), CFO and Treasurer Paul Kim reported a Form 4 transaction involving 1,168 shares of common stock on 2026-08-26. The shares were withheld to satisfy tax withholding obligations triggered by the vesting of restricted stock units, not sold in an open-market trade. After this tax-withholding disposition, Kim’s directly held stake is 358,630 shares of common stock.
Fulgent Genetics, Inc. (FLGT) reported an insider transaction by President and COO Jian Xie. On 2026-08-27, Xie sold 1,193 shares of common stock at a weighted-average price of $19.9053 per share to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 26, 2024. After this sale, Xie directly held 362,051 shares and had an additional 220,816 shares held indirectly through The Hsieh Family Dynasty Trust, for which he serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.
Fulgent Genetics, Inc. (FLGT) reported that Chief Scientific Officer Hanlin Gao sold 939 shares of common stock on August 27, 2026, in an open-market transaction at a weighted-average price of $19.9053 per share, in multiple trades between $19.83 and $20.00. According to the disclosure, the sale was made to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 26, 2024. Following this sale, Gao directly holds 987,790 shares of Fulgent Genetics common stock.
Fulgent Genetics, Inc. reports that CFO and Treasurer Paul Kim had 2,747 shares of common stock withheld on July 26, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units assumed in a 2022 merger. After this tax withholding disposition, he directly owns 359,798 shares.
Fulgent Genetics, Inc. President and COO Jian Xie reported a tax‑withholding disposition of 4,361 shares of common stock on July 26, 2026, at $19.67 per share, to cover taxes from vesting restricted stock units. After this, he directly held 363,244 shares, with an additional 220,816 shares held indirectly through The Hsieh Family Dynasty Trust, where he serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.
Fulgent Genetics, Inc. (FLGT) reports that Chief Scientific Officer Hanlin Gao had 1,645 shares of Common Stock withheld on July 26, 2026 to satisfy tax withholding obligations from the vesting of restricted stock units assumed in a prior merger, leaving him with 988,729 shares directly held.
Fulgent Genetics, Inc. President and COO Jian Xie reported an open-market sale of 2,146 shares of common stock at a weighted-average price of $17.8855 per share on June 2, 2026. According to the disclosure, the shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 25, 2025.
Following the sale, Xie holds 367,605 shares of Fulgent Genetics common stock directly and an additional 220,816 shares indirectly through The Hsieh Family Dynasty Trust, where he serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.
Fulgent Genetics CFO Paul Kim reported a routine share disposition related to tax withholding. On June 1, 2026, 2,087 shares of common stock were withheld at $18.09 per share to satisfy tax obligations triggered by the vesting of restricted stock units granted on February 25, 2025. After this withholding, Kim directly holds 362,545 shares of Fulgent Genetics common stock, indicating the transaction was a small, non-market event tied to compensation rather than an open-market sale.
Fulgent Genetics, Inc. Chief Scientific Officer Hanlin Gao reported an open-market sale of 1,688 shares of common stock at a weighted-average price of $17.8855 per share. The shares were sold to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. Following this transaction, Gao directly holds 990,374 shares of Fulgent Genetics common stock.
Fulgent Genetics CEO Ming Hsieh reported a Form 4 showing shares withheld for taxes on vested stock awards, not an open‑market trade. On June 1, 2026, 4,392 shares of common stock were disposed of at $18.09 per share to satisfy tax withholding obligations from restricted stock units granted on February 25, 2025.
After this tax-withholding disposition, Hsieh directly holds 893,293 common shares. He also has substantial indirect holdings through family and trust structures, including shares held by the Ming Hsieh Trust, the Dynasty Trust, a Uniform Transfers to Minor Act account, and an immediate family member residing in the same household.
Fulgent Genetics, Inc. President and COO Jian Xie reported an open-market sale of 1,201 shares of common stock on May 27, 2026 at a weighted-average price of $17.60 per share. The shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 26, 2024.
Following the sale, Xie directly holds 369,751 shares of Fulgent Genetics common stock. An additional 220,816 shares are held indirectly by The Hsieh Family Dynasty Trust, where Xie serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.
Fulgent Genetics, Inc. CFO and Treasurer Paul Kim reported a routine tax-related share disposition. On May 26, 2026, 1,168 shares of common stock were withheld to cover tax obligations arising from the vesting of restricted stock units granted on February 26, 2024. After this withholding, Kim directly holds 364,632 common shares.
Fulgent Genetics, Inc. Chief Scientific Officer Hanlin Gao reported an open-market sale of common stock. On May 27, 2026, he sold 945 shares at a weighted-average price of $17.60 per share to satisfy tax withholding obligations from vested restricted stock units. After this transaction, Gao directly held 992,062 shares of Fulgent Genetics common stock, so the sale represents only a small fraction of his overall stake.
Fulgent Genetics, Inc. director and Chief Executive Officer Ming Hsieh reported a routine tax withholding event related to equity compensation. Upon vesting of restricted stock units granted on February 26, 2024, 2,949 shares of common stock were withheld at $17.67 per share to satisfy tax obligations, leaving him with 897,685 directly held shares.
He also reports substantial indirect holdings, including shares held by The Ming Hsieh Trust, the Dynasty Trust, a Uniform Transfers to Minor Act account, and an immediate family member in the same household, with individual positions such as 7,895,115 shares and 220,816 shares held via trusts.
Fulgent Genetics director Michael Nohaile reported new equity awards. He received 5,558 shares of common stock as a grant, bringing his direct holdings to 24,578 shares. He was also granted options on 8,426 shares at an exercise price of $16.19 per share, expiring on May 13, 2036.
The 5,558 restricted stock units and the 8,426 options both vest over four years. One quarter vest 12 months after May 14, 2026, and the remainder vest in equal quarterly installments over the following 36 months, contingent on continued service with the company.
Dong Linda reported acquisition or exercise transactions in this Form 4 filing.
Fulgent Genetics director Linda Dong reported receiving 11,117 shares of Common Stock as a grant of restricted stock units at no cash cost. The award vests over four years, with 1/4 vesting 12 months after May 14, 2026 and the rest quarterly, leaving her with 38,758 directly held shares after the grant.
GROVES REGINA E reported acquisition or exercise transactions in this Form 4 filing.
Fulgent Genetics director Regina E. Groves received a grant of 11,117 shares of common stock in the form of restricted stock units. These units were awarded at no cash cost per share and increased her direct holdings to 28,099 shares after the transaction.
The restricted stock units vest over four years. One quarter of the shares vest 12 months after May 14, 2026, and the remaining three quarters vest in equal 1/16 portions at the end of every three-month period over the following 36 months, subject to her continued service with the company.
Fulgent Genetics, Inc. Chief Scientific Officer Hanlin Gao reported a routine tax-related share disposition. On the vesting of restricted stock units assumed in a prior merger, 1,645 shares of common stock were withheld to cover tax withholding obligations at $16.31 per share.
Following this tax-withholding event, Gao directly holds 993,007 shares of Fulgent Genetics common stock. This withholding is an administrative mechanism tied to equity compensation and does not represent an open-market purchase or sale.
Fulgent Genetics, Inc. President and COO Jian Xie reported routine tax-related share withholding tied to equity compensation. On this Form 4, 4,361 shares of common stock were withheld at $16.31 per share to satisfy tax withholding obligations arising from the vesting of restricted stock units assumed in a prior merger.
After this tax-withholding disposition, Xie holds 370,952 common shares directly. In addition, a trust associated with him, The Hsieh Family Dynasty Trust, holds 220,816 shares indirectly; Xie serves on the trust’s investment committee and disclaims beneficial interest except for any pecuniary interest.
Fulgent Genetics, Inc. CFO and Treasurer Paul Kim reported a routine tax-related share disposition. On April 26, 2026, 2,747 shares of common stock were withheld to satisfy tax withholding obligations arising from the vesting of previously assumed restricted stock units under a prior merger agreement. Following this withholding, Kim directly holds 365,800 shares of Fulgent common stock, indicating he retained a substantial equity position and did not report an open-market sale in this filing.
Fulgent Genetics, Inc. director and CEO Ming Hsieh, through The Ming Hsieh Trust, unwound a prepaid variable forward arrangement involving 750,000 shares of common stock. The trust had previously entered this forward contract with an unaffiliated bank in August 2023.
On March 9, 2026, the Hsieh Trust elected to cancel the agreement for all 750,000 shares and paid an aggregate of $10,708,875 to the bank. After this payment and cancellation, those 750,000 shares held by the trust are no longer pledged to the bank.
Following the reported positions, Ming Hsieh holds 900,634 shares directly and has additional indirect holdings, including 7,895,115 and 220,816 shares held by trusts, plus smaller positions of 1,000 shares each in a minor’s account and by an immediate family member.
Fulgent Genetics, Inc. director and CEO Ming Hsieh, a more than ten percent owner, restructured a prior derivative arrangement tied to company stock. A trust associated with him had entered a prepaid variable forward contract in 2023 covering up to 750,000 shares of common stock.
On March 9, 2026, The Ming Hsieh Trust cancelled this agreement for all 750,000 shares and paid the counterparty an aggregate of $10,708,875. After this payment, those 750,000 shares are no longer pledged to the bank and remain held by entities associated with Hsieh.
Following these actions, Hsieh holds 900,634 common shares directly, and additional common shares indirectly, including 7,895,115 by trust, 220,816 by trust, 1,000 in a Uniform Transfers to Minors Act account, and 1,000 held by an immediate family member.
Fulgent Genetics President and COO Jian Xie reported several tax-related share withholdings of company common stock. On February 26, 2026, 1,140 shares were disposed of at $24.7600 per share to cover tax obligations from vesting restricted stock units. On March 1, 2026, additional tax-withholding dispositions of 1,079 and 8,147 shares occurred at $15.3300 per share. After these transactions, his direct holdings were reported as 375,313 shares of common stock. Separately, 220,816 shares are held indirectly by The Hsieh Family Dynasty Trust, for which Mr. Xie serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.
Fulgent Genetics, Inc. CFO and Treasurer Paul Kim reported several tax-withholding dispositions of common stock tied to previously granted restricted stock units. On February 26 and March 1, 2026, shares were withheld at prices of $24.76 and $15.33 to cover associated tax obligations rather than open-market sales.
Fulgent Genetics Chief Scientific Officer Hanlin Gao reported tax-withholding share dispositions related to restricted stock unit vesting. On February 26, 2026 and March 1, 2026, several small blocks of common stock were withheld at prices of $24.76 and $15.33 per share to cover tax obligations, leaving Gao with direct ownership of just under 1.0 million shares after these administrative transactions.
Fulgent Genetics, Inc. director and CEO Ming Hsieh reported tax-related share dispositions rather than open-market sales. On March 1, 2026, 17,566 common shares at $15.33 per share were withheld to cover tax obligations from vested restricted stock units, leaving him with 900,634 directly held shares.
On February 26, 2026, a prior tax-withholding disposition of 2,949 shares at $24.76 per share left him with 918,200 directly held shares at that time. Indirect holdings as of that date include 7,895,115 shares held by the Dynasty Trust, 220,816 by The Ming Hsieh Trust, and 1,000-share positions in a Uniform Transfers to Minors Act account and an immediate family member’s account.
Fulgent Genetics CFO Paul Kim reported equity awards and related tax withholdings in company stock. On February 23–24, 2026, he acquired multiple common stock grants tied to time-based and performance-based restricted stock units that vested upon meeting performance milestones from awards granted in 2023, 2024, and 2025.
To satisfy tax withholding obligations triggered by these vestings, shares were withheld at prices around $23 per share rather than sold on the open market. A new restricted stock unit grant will vest over three years, with one-third vesting 12 months after March 1, 2026 and the remainder in quarterly installments, subject to continued service.
Fulgent Genetics, Inc. President and COO Jian Xie reported a mix of stock awards and tax-related share withholdings. On February 24, 2026, he acquired several blocks of common stock at no cost through vested performance-based restricted stock units granted in 2023, 2024, and 2025.
He also received a new grant of 31,962 restricted stock units that vest over three years starting 12 months after March 1, 2026. Shares totaling 3,163, 8,254, 14,751 and 655 were withheld at prices around $23 per share to satisfy tax obligations. Additional indirect holdings are reported in The Hsieh Family Dynasty Trust, where Xie notes only a pecuniary interest.
Fulgent Genetics Chief Scientific Officer Hanlin Gao reported equity awards and related tax withholdings in company stock. On February 24, 2026, he acquired 4,891, 12,762, 22,806 and 26,661 shares of common stock at $0 per share through grants and vesting of restricted stock units, including performance-based awards tied to milestones from grants made in 2023, 2024 and 2025.
To cover tax obligations from these vestings, 2,489, 4,661, 8,149 and 403 shares were withheld at prices of about $23.09 and $23.01 per share. After these transactions, Gao directly owned 976,316 to 1,002,977 shares across the reported line items, reflecting routine compensation-related activity rather than open-market buying or selling.
Fulgent Genetics, Inc. director and CEO Ming Hsieh reported multiple equity-related transactions in the company’s common stock. On February 24, 2026, he acquired shares at a price of $0.00 per share through grants and vesting of restricted stock units tied to performance milestones and service-based conditions.
On the same date, shares were also disposed of at $23.09 per share, and on February 23, 2026 at $23.01 per share, to satisfy tax withholding obligations triggered by those vestings, rather than open‑market sales. The filing also shows significant indirect holdings through the Dynasty Trust, The Ming Hsieh Trust, a Uniform Transfers to Minors Act account, and an immediate family member’s account, with varying levels of voting and dispositive power as described in the footnotes.
Fulgent Genetics Chief Scientific Officer Hanlin Gao reported a tax-related share withholding. On January 26, 2026, 1,331 shares of common stock were withheld at $27.53 per share to cover taxes from vested restricted stock units. After this, Gao directly owned 951,559 shares of Fulgent Genetics common stock.
Fulgent Genetics, Inc. President and COO Jian Xie reported a tax-related share withholding on common stock. On January 26, 2026, 4,711 shares of Fulgent Genetics common stock were withheld at $27.53 per share to cover tax obligations from the vesting of restricted stock units tied to a prior merger agreement.
After this transaction, Xie directly beneficially owns 332,038 common shares. In addition, 220,816 common shares are reported as indirectly owned through The Hsieh Family Dynasty Trust, where Xie serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.
Fulgent Genetics CFO Paul Kim reported a routine tax-related share withholding. On January 26, 2026, 3,004 shares of Fulgent Genetics common stock were withheld at $27.53 per share to cover tax obligations arising from the vesting of previously granted restricted stock units.
After this withholding, Kim beneficially owned 328,146 shares of common stock in direct form. The transaction was coded "F," indicating a tax withholding event linked to equity compensation rather than an open-market sale.
Fulgent Genetics (FLGT) filed a Form 4 reporting that Chief Executive Officer, director and 10% owner Ming Hsieh had 2,116 shares of common stock withheld on 11/23/2025 to cover tax obligations from vesting restricted stock units granted on February 23, 2023. After this withholding, he directly beneficially owns 802,165 common shares. He also has significant indirect holdings, including 7,895,115 shares held by the Dynasty Trust, 220,816 shares held by The Ming Hsieh Trust, and two 1,000-share Uniform Transfers to Minor Act accounts for which he serves as custodian.
Fulgent Genetics (FLGT) reported an insider equity transaction by its Chief Financial Officer and Treasurer, Paul Kim. On 11/23/2025, 671 shares of common stock were withheld at a price of $30 per share to cover tax obligations that arose when previously granted restricted stock units vested. After this tax withholding transaction, Paul Kim beneficially owned 333,447 shares of Fulgent Genetics common stock directly. This filing documents a routine administrative event related to equity compensation rather than an open-market purchase or sale.
Fulgent Genetics, Inc. reported an insider transaction by its President and COO on a Form 4. On 11/24/2025, the officer sold 681 shares of common stock at a weighted-average price of $30.473. The filing explains that the sale was made to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 23, 2023.
After this transaction, the officer beneficially owned 339,087 shares of Fulgent Genetics common stock directly and 220,816 shares indirectly through The Hsieh Family Dynasty Trust. The trust holdings are attributed because the officer serves on its investment committee, while disclaiming beneficial interest except for any pecuniary interest.
Fulgent Genetics (FLGT) insider transaction: the company’s Chief Scientific Officer reported a small sale of common stock tied to tax obligations. On 11/24/2025, the officer sold 535 shares of Fulgent Genetics common stock at a weighted-average price of $30.473 per share. The sale was coded as a disposition of securities in an open-market transaction.
According to the disclosure, these shares were sold solely to cover tax withholding that arose when previously granted restricted stock units vested. After this transaction, the officer reported beneficial ownership of 954,908 shares of Fulgent Genetics common stock, held directly.
Fulgent Genetics, Inc. (FLGT) president and COO reported insider transactions involving the company’s common stock. On 11/19/2025, the reporting person sold 10,000 shares of common stock at a weighted-average price of $29.0983 per share for year-end tax planning. On the same date, 10,000 shares were transferred as a gift to the James and Karena Xie Family Foundation, over which the reporting person has voting and investment power.
After these transactions, the reporting person directly owned 339,768 shares of Fulgent Genetics common stock and indirectly held 220,816 shares through The Hsieh Family Dynasty Trust. The filing reflects personal portfolio and charitable planning by a senior executive rather than changes to the company’s operations.
Fulgent Genetics (FLGT) — Form 4: The company’s Chief Scientific Officer reported a tax‑withholding transaction on 10/26/2025. 1,642 shares of common stock were withheld (code F) to cover taxes upon vesting of restricted stock units related to the November 7, 2022 merger. The withholding was recorded at a price of $23.74 per share.
After this administrative transaction, the reporting person beneficially owns 955,443 shares of FLGT common stock, held directly.
Fulgent Genetics (FLGT) — Form 4 insider transaction: the company’s CFO and Treasurer reported a tax-related share withholding tied to equity vesting. On 10/26/2025, 2,743 shares of common stock were withheld under transaction code F at a price of $23.74 to satisfy tax obligations upon the vesting of restricted stock units assumed in the November 7, 2022 merger agreement.
Following this administrative transaction, the reporting person beneficially owned 334,118 shares directly. This filing reflects routine tax withholding associated with stock-based compensation rather than an open-market purchase or sale.
Fulgent Genetics (FLGT) reported an insider transaction by its President and COO. On 10/26/2025, 4,353 shares of common stock were withheld at $23.74 per share to cover taxes upon the vesting of previously assumed restricted stock units (Transaction Code F).
After the transaction, the reporting person beneficially owned 359,768 shares directly and 220,816 shares indirectly through The Hsieh Family Dynasty Trust. The filing notes the reporting person disclaims beneficial interest in the trust except for any pecuniary interest.